Creative Planning Acquires 7,742 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Creative Planning increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 48.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,714 shares of the medical equipment provider’s stock after buying an additional 7,742 shares during the quarter. Creative Planning’s holdings in Lantheus were worth $1,904,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LNTH. Daiwa Securities Group Inc. acquired a new stake in Lantheus during the 1st quarter valued at $1,269,000. Nordea Investment Management AB grew its holdings in shares of Lantheus by 42.6% during the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after buying an additional 14,147 shares in the last quarter. Hancock Whitney Corp raised its holdings in shares of Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Lantheus during the second quarter worth $290,000. Finally, Pitcairn Co. increased its stake in Lantheus by 117.0% in the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after buying an additional 4,509 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $106.60 on Tuesday. The stock has a market cap of $7.39 billion, a PE ratio of 16.27 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The business’s 50-day moving average price is $103.67 and its two-hundred day moving average price is $88.09.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted $1.40 earnings per share. As a group, analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LNTH shares. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Truist Financial lowered their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, JMP Securities reduced their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.